Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial

MT Newswires Live06-02

Rezolute (RZLT) said Tuesday that six of eight participants currently enrolled in a phase 3 trial of ersodetug in uncontrolled hypoglycemia caused by tumor hyperinsulinism have already met the responder criterion for the study's primary endpoint.

The primary endpoint of the study, which aims to enroll 16 patients with insulinoma or non-islet cell tumors, is the number of participants achieving at least a 50% reduction from baseline in intravenous glucose requirements within the 8-week pivotal treatment phase, the company said.

Rezolute said ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.

Topline results for the fully enrolled open-label phase 3 study are expected in H2, Rezolute said.

Shares of Rezolute were up 2.2% in premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment